Pharmacological treatment of obesity: Therapeutic strategies

Journal of Medicinal Chemistry

Volumn 42, Issue 2, 1999, Pages 181-201

  Kordik, Cheryl P ^a,b   Reitz, Allen B ^a,c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHOXY]PHENYLACETIC ACID; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY] N (2 METHOXYETHYL)PHENOXYACETAMIDE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; A 71378; AD 9677; ALPHA INTERMEDIN; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; ARL 14294; ARL 15849; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BMS 187413; BMS 210285; CARBOXYPEPTIDASE H; CP 114271; CP 331679; DEXFENFLURAMINE; ENZYME INHIBITOR; FENFLURAMINE; FR 149175; HEXYLUREA; MAZINDOL; MELANOCORTIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N TERT BUTYLOXYCARBONYLTRYPTOPHYL[NEPSILON (2 METHYLPHENYLAMINOCARBONYL)LYSYL]ASPARTYL N METHYLPHENYLALANINAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENTERMINE; PHENYLPROPANOLAMINE; PHOSPHOLIPASE A2; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SR 59062A; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ADRENERGIC SYSTEM; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; FEEDING BEHAVIOR; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SATIETY; SEROTONINERGIC SYSTEM;

ADIPOSE TISSUE; ADRENERGIC AGENTS; ANIMALS; APPETITE DEPRESSANTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENERGY INTAKE; GASTROINTESTINAL AGENTS; HUMANS; OBESITY; SEROTONIN AGENTS;

EID: 0032907895     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980521l     Document Type: Review

References (239)

1. Wickelgren, I. Obesity: How Big a Problem? Science 1998, 280, 1364-1367.
2. Bray, G. A. Clinical Use of Drugs in the Treatment of Obesity. In Nutrition, Endocrinology, and Disease; Bray, G. A., Ryan, D. H., Eds.; Pennington Center Nutrition Series; Louisiana State University Press: Baton Rouge, 1995; Vol. 4, pp 131-176.
3. World Health Organization. Obesity: Preventing and Managing the Global Epidemic; World Health Organization: Geneva, 1998.
4. Solomon, C. G.; Manson, J. E. Obesity and Mortality: A Review of the Epidemiologic Data. Am. J. Clin. Nutr. 1997, 66, 1044S-1050S.
5. Manson, J. E.; Willett, W. C.; Stampfer, M. J.; Colditz, G. A.; Hunter, D. J.; Hankinson, S. E.; Hennekens, C. H.; Speizer, F. E. Body Weight and Mortality Among Women. N. Engl. J. Med. 1995, 11, 677-685.
6. Eckel, R. H.; Krauss, R. M. American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease. Circulation 1898, 97, 2099-2100.
7. Gibbs, W. W. Gaining on Fat. Sci. Am. 1996, 88-94.
8. Taubes, G. As Obesity Rates Rise, Experts Struggle to Explain Why. Science 1998, 280, 1367-1368.
9. Atkinson, R. L. Guidelines for the Initiation of Obesity Treatment. J. Nutr. Biochem. 1998, 9, 547-552.
10. Atkinson, R. L. Use of Drugs in the Treatment of Obesity. Annu. Rev. Nutr. 1997, 17, 383-403.
11. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical Guidelines on the Identification, evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary, Am. J. Clin. Nutr. 1998, 68, 899-917.
12. Hill, J. O.; Peters, J. C. Environmental Contributions to the Obesity Epidemic. Science 1998, 280, 1371-1374.
13. Comuzzie, A. G.; Allison, D. B. The Search for Human Obesity Genes. Science 1998, 280, 1374-1377.
14. Weiser, M.; Frishman, W. H.; Michaelson, M. D.; Abdeen, M. A. The Pharmacological Approach to the Treatment of Obesity. J. Clin. Pharmacol. 1997, 37, 453-473.
15. Chagnon, Y. C. The Human Obesity Gene Map: The 1997 Update. Obes. Res. 1998, 6, 76-92.
16. Winick, J. D.; Friedman, J. M. Microsatellite Marker Content Mapping of 12 Candidate Genes for Obesity: Assembly of Seven Screening Panels for Automated Genotyping. Genome Res. 1998, 8, 985-994.
17. Woods, S. C.; Seeley, R. J.; Porte, D., Jr.; Schwartz, M. W. Signals that Regulate Food Intake and Energy Homeostasis. Science 1998, 280, 1378-1383.
18. Rosenbaum, M.; Nicolson, M.; Hirsch, J.; Heymsfield, S. B.; Gallagher, D.; Chu, F.; Leibel, R. L. Effects of Gender, Body Composition, and Menopause on Plasma Concentrations of Leptin. J. Clin. Endocrinol. Metab. 1996, 81, 3424.
19. Flynn, M. C.; Scott, T. R.; Pritchard, T. C.; Plata-Salamán, C. R. Mode of Action of OB Protein (Leptin) on Feeding. Am. J. Physiol. 1998, 275, R174-R179.
20. Kahler, A.; Geary, N.; Eckel, L. A.; Campfield, L. A.; Smith, F. J.; Langhans, W. Chronic Administration of OB Protein Decreases Food Intake by Selectively Reducing Meal Size in Male Rats. Am. J. Physiol. 1998, 275, R180-R185.
21. Eckel, L. A.; Langhans, W.; Kahler, A.; Campfield, L. A.; Smith, F. J.; Geary, N. Chronic Administration of OB Protein Decreases Food Intake by Selectively Reducing Meal Size in Female Rats. Am. J. Physiol. 1998, 275, R186-R193.
22. Stephens, T. W.; Basinski, M.; Brìstow, P. K.; Bue-Valleskey, J. M.; Burgett, S. G.; Craft, L.; Hale, J.; Hoffmann, J.; Hsiung, H. M.; Kriausciunas, A.; MacKellar, W.; Rosteck, P. R., Jr.; Schoner, B.; Smith, D.; Tinsley, F. C.; Zhang, X.-Y.; Helman, M. The Role of Neuropeptide Y in the Antiobesity Action of the Obese Gene Product. Nature 1995, 377, 530-532.
23. Bray, G.; Bouchard, C. Genetics of Obesity: Research Directions. FASEB J. 1997, 11, 937-945.
24. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J. M. Positional Cloning of the Mouse Obese Gene and Its Human Homologue. Nature 1994, 372, 425-432.
25. Campfield, L. A.; Smith, F. J.; Guisez, Y.; Devos, R.; Burn, P. Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks. Science 1995, 269, 546-549.
26. Halaas, J. L.; Gajiwala, K. S.; Maffei, M.; Cohen, S. L.; Chait, B. T.; Rabinowi, D.; Lallone, R. L.; Burley, S. K.; Friedman, J. M. Weight-Reducing Effects of the Plasma-Protein Encoded by the Obese Gene. Science 1995, 269, 543-546.
27. Pelleymounter, M. A.; Cullen, M. J.; Baker, M. B.; Hecht, R.; Winters, D.; Boone, T.; Collins, F. Effects of the Obese Gene-Product on Body-Weight Regulation in ob/ob Mice. Science 1995, 269, 540-543.
28. Xin, X. G.; Huang, X.-F. Down-Regulated NPY Receptor Subtype-5 mRNA Expression in Genetically Obese Mouse Brain. NeuroReport 1998, 9, 737-741.
29. Chen, H.; Charlat, O.; Tartaglia, L. A.; Woolf, E. A.; Weng, X.; Ellis, S. J.; Lakey, N. D.; Culpepper, J.; Moore, K. J.; Breitbart, R. E.; Duyk, G. M.; Tepper, R. I.; Morgenstein, J. P. Evidence that the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in dbldb Mice. Cell 1996, 84, 491-495.
30. Lee, G. H.; Proenca, R.; Montez, J. M.; Carroll, K. M.; Darvishzadeh, J. G.; Lee, J. I.; Friedman, J. M. Abnormal Splicing of the Leptin Receptor in Diabetic Mice. Nature 1996, 379, 632-635.
31. vyI-Mice; Ectopic Expression of the Agouti Gene. FASEB J. 1994, 8, 479-488.
32. Lu, D.; Willard, D.; Patel, I. R.; Kadwell, S.; Overton, L.; Kost, T.; Luther, M.; Chen, W.; Woychik, R. P.; Wilkison, W. O. Agouti Protein is an Antagonist of the Melanocyte-Stimulating-Hormone Receptor. Nature 1994, 371, 799-802.
33. Mountjoy, K. G.; Mortrud, M. T.; Low, M. J.; Simerly, R. B.; Cone, R. D. Localization of the Melanocortin Receptor (MC4-R) in Neuroendocrine and Autonomie Control Circuits in Brain. Mol. Endocrinol. 1994, 8, 1298-1308.
34. Coleman, D. L.; Eicher, E. M. Fat (fat) and Tubby (tub); Two Autosomal Recessive Mutations Causing Obesity Problems in the Mouse. J. Hered. 1990, 88, 424-427.
35. Naggert, J. K.; Fricker, L. D.; Varlamov, O.; Nishina, P. M.; Rouille, Y.; Steiner, D. F.; Carroll, R. J.; Paigen, B. J.; Leiter, E. H. Hyperproinsulinaemia in Obese fat/fat Mice Associated with a Carboxypeptidase E Mutation Which Reduces Enzyme Activity. Nature Genet. 1995, 10, 135-142.
36. Cool, D. R.; Normant, E.; Shen, F.; Chen, H.; Pannell, L.; Zhang, Y.; Loh, Y. P. Carboxypeptidase E is a Regulated Secretory Pathway Sorting Receptor: Genetic Obliteration Leads to Endocrine Disorders in Cpe/fat Mice. Cell 1997, 88, 73-83.
37. Triscari, J.; Tilley, J.; Hogan, S. The Pharmacological Treatment of Obesity. Annu. Rep. Med. Chem. 1988, 23, 191-200.
38. Silverston, T. Appetite Suppressants: a Review. Drugs 1992, 43, 820-836.
39. Wellman, P. J.; Davies, B. T. Reversal of Cirazoline-Induced and Phenylpropanolamine-Induced Anorexia by the Alpha-1-Receptor Antagonist Prazosin. Pharmacol. Biochem. Behav. 1992, 42, 97-100.
40. Schteingart, D. Effectiveness of Phenylpropanolamine as an Adjunct in the Dietary Management of Obesity. Int. J. Obes. 1990, 14 (Suppl. 2), 48.
41. Bray, G. A. Evaluation of Drugs for Treating Obesity. Obes. Res. 1995, 3, 425S-434S.
42. Hoekenega, M. T.; O'Dillon, R. H.; Leyland, H. M. A Comprehensive Review of Diethylpropion Hydrochloride. In Central Mechanisms ofAnorectic Drugs; Garattini, S., Samanin, R., Eds.; Raven Press: New York, 1978; pp 391-404.
43. Anonymous Drugs Used in Obesity. AMA Drug Evaluations Annual; American Medical Association: Chicago, 1995; p 2439.
44. Onishi, T. Clinical Evaluation of Mazindol, an Anorexant, on Obesity. Int. J. Obes. 1990, 14 (Suppl. 12), 34.
45. Nathan, C. Serotonin Agonists. In Obesity; Bjornstorp, P., Brodoff, B. N., Eds.; JB Lippincott: New York, 1992; pp 751-761.
46. Garattini, S.; Bizzi, A.; Codegoni, A. M.; Mennini, T. Progress Report on the Anorexia Induced by Drugs Believed to Mimic Some of the Effects of Serotonin on the Central Nervous System. Am. J. Clin. Nutr. 1992, 55, 160S-166S.
47. Kennett, G. A. 5-HT Drugs and Eating Disorders. Drugs 1998, 1, 456-470.
48. Connolly, H. M.; Crary, J. L.; McGoon, M. D.; Hensrud, D. D.; Edwards, B. S.; Edwards, W. D.; Schaff, H. V. Valvular Heart Disease Associated with Fenfluramine-Phentermine. N. Eng. J. Med. 1997, 337, 581-588.
49. Davis, R.; Faulds, D. Dexfenfluramine: An Updated Review of Its Therapeutic Use in the Management of Obesity. Drugs 1996, 52, 696-724.
50. Grignaschi, G.; Samanin, R. Role of 5-HT Receptors in the Effect of d-Fenfluramine on Feeding Patterns in the Rat. Eur. J. Pharmacol. 1992, 212, 287-289.
51. Grignaschi, G.; Neill, J. C.; Petrini, A. Feeding Pattern Studies Suggest that d-Fenfluramine and Sertraline Specifically Enhance the Satiety of Rats. Eur. J. Pharmacol. 1992, 211, 137-142.
52. Blundell, J. E.; Hill, A. J. Dexfenfluramine and Appetite in Humans. Int. J. Obes. 1992, 16 (Suppl. 3), 51-59.
53. Bever, K. A.; Perry, P. J. Dexfenfluramine Hydrochloride: an Anorexigenic Agent. Am. J. Health-Syst. Pharm. 1997, 54, 2059-2072.
54. Finer, N.; Finer, S.; Naumova, R. P. Drug Therapy After Very Low-Calorie Diets. Am. J. Clin. Nutr. 1992, 56, 195S-198S.
55. Guy-Grand, B.; Crepaldi, G.; Lefebvre, P.; Apfelbaum, M.; Gries, A.; Turner, P. International Trial of Long-Term Dexfenfluramine in Obesity. Lancet 1989, 1142-1145.
56. Goldstein, D. J.; Rampey, A. H.; Enas, G. G.; Potvin, J. H.; Fludzinski, L. A.; Levine, L. R. Fluoxetine: a Randomized Clinical Trial in the Treatment of Obesity. Int. J. Obes. 1994, 18, 129-135.
57. McGuirk, J.; Silverstone, T. The Effect of the 5-HT Reuptake Inhibitor Fluoxetine on Food Intake and Body Weight in Healthy Male Subjects. Int. J. Obes. 1990, 14, 361-372.
58. Simansky, K. J.; Vaidya, A. H. Behavioral Mechanisms for the Anorectic Action of the Serotonin (5-HT) Uptake Inhibitor Sertraline in Rats: Comparison with Directly Acting 5-HT Agonists. Brain Res. Bull. 1990, 25, 953-960.
59. Nielsen, J. A.; Chapin, D. S.; Johnson, J. L.; Torgersen, L. K. Sertraline, A Serotonin-Uptake Inhibitor, Reduces Food Intake and Body Weight in Lean Rats and Genetically Obese Mice. Am. J. Clin. Nutr. 1992, 55, 185-188.
60. Rasmussen, J. G. C.; Johnson, A. M.; Stewart, B.; Palmer, K. J. Comparative Effects of the Selective Serotonin Uptake Inhibitors Paroxetine and Fluoxetine on Food Intake in Rats and Effect of Paroxetine on Body Weight in Depressed Patients. J. Psychopharmacol. 1990, 4, 4.
61. Szkudlarek, J.; Elsborg, L. Treatment of Severe Obesity with a Highly Selective Serotonin Reuptake Inhibitor as a Supplement to a Low Calorie Diet. Int. J. Obes. Relat. Metab. Disord. 1993, 17, 681-683.
62. Fernstrom, M. H.; Massoudi, M.; Kupfer, D. J. Fluvoxamine and Weight Loss. Biol. Psychiatry 1988, 24, 948-949.
63. Dourish, C. T.; Clarke, M. L.; Iversen, S. D. 8-OH-DPAT Elicits Feeding and Not Chewing: Evidence from Liquid Diet Studies and a Diet Choice Test. Psychopharmacology 1988, 95, 185-188.
64. Raykel, R. E. Long-Term Buspirone Therapy for Chronic Therapy: A Multicentre International Study to Determine Safety. South. Med. J. 1990, 83, 194-198.
65. 1A Receptor Antagonist. Behavior. Brain Res. 1996, 73, 337-353.
66. Weintraub, M.; Hasday, J. D.; Mushlin, A. I.; Lockwood, D. H. A Double-Blind Clinical Trial in Weight Control: Use of Fenfluramine and Phentermine Alone and in Combination. Arch. Intern. Med. 1984, 144, 1143-1148.
67. Abenhaim, L.; Moride, Y.; Brenot, F.; Rich, S.; Benichou, J.; Kurz, X.; Higenbottam, T.; Oakley, C.; Wouters, E.; Aubier, M. Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. N. Engl. J. Med. 1996, 335, 609-616.
68. McCann, U. D.; Seiden, L. S.; Rubin, L. J.; Ricaurte, G. A. Brain Serotonin Neurotoxicity and Primary Pulmonary Hypertension from Fenfluramine and Dexfenfluramine. J. Am. Med. Assoc. 1997, 278, 666-672.
69. Mezitis, S. G.; Aronne, L. J. Pharmacotherapy of Obesity. Curr. Opin. Endocrinol. Diabetes 1997, 4, 407-411.
70. Atkinson, R. L.; Blank, R. C.; Loper, J. F.; Schumacher, D.; Lutes, R. A. Combined Drug Treatment of Obesity. Obes. Res. 1995, 3, 497S-500S.
71. Pedrinola, F.; Sztejnsznajd, C.; Lima, N.; Halpern, A.; Medeiros-Neto, G. The Addition of Dexfenfluramine to Fluoxetine in the Treatment of Obesity: a Randomized Clinical Trial. Obes. Res. 1996, 4, 549-554.
72. Luque, C. A.; Rey, J. A.; Fernandez, A. Focus on Sibutramine: a New Anorectic Agent for the Treatment of Obesity. Formulary 1997, 32, 1025-1039.
73. 3H]-5-HT Uptake: Effect of Administration of Various Antidepressant Treatments. Neuropharmacology 1993, 32, 737-743.
74. 3H]-Noradrenaline Uptake and Effect of DSP-4-Lesioning and Antidepressant Treatments. Neuropharmacology 1996, 35, 63-70.
75. Fantino, M.; Souquet, A. M. Effects of Metabolites 1 and 2 of Sibutramine on the Short-Term Control of Food Intake in the Rat. Int. J. Obes. 1995, 1 (Suppl. 2), 145.
76. Stock, M. J. Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent. Int. J. Obes. 1991, 21 (Suppl. 1), S25-S29.
77. Connoley, I. P.; Frost, I.; Heal, D. J.; Stock, M. J. Role of β-Adrenoreceptors in Mediating the Thermogenic Effects of Sibutramine. Br. J. Pharmacol. 1996, 117, 170P.
78. Lean, M. E. J. Sibutramine-A Review of Clinical Efficacy. Int. J. Obes. 1997, 21, S30-S36.
79. Griffiths, J.; Brynes, A. E.; Frost, G.; Bloom, S. R.; Finer, N.; Jones, S. P.; Romanec, F. M. Sibutramine in the Treatment of Overweight Non-Insulin Dependent Diabetics. Int. J. Obes. 1995, 19, 41.
80. Rolls, B. J.; Shide, D. J.; Thorwart, M. L.; Ulbrecht, J. S. Sibutramine Reduces Food Intake in Non-Dieting Women with Obesity. Obes. Res. 1998, 6, 1-11.
81. King, D. J.; Devaney, N. Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant, in Healthy Volunteers. Br. J. Pharmacol. 1988, 26, 607-611.
82. Guerciolini, R. Mode of Action of Orlistat. Int. J. Obes. 1997, 21 (Suppl. 3), S12-S23.
83. Malone, M. Orlistat. Drugs 1998, 1, 232-235.
84. James, W. P. T.; Avenell, A.; Broom, J.; Whitehead, J. A One-Year Trial to Assess the Value of Orlistat in the Management of Obesity. Int. J. Obes. 1997, 21 (Suppl. 3), S24-S30.
85. Tonstad, S.; Pometta, D.; Erkelens, D. W.; Ose, L.; Moccetti, T.; Schouten, J. A. The Effect of the Gastrointestinal Lipase Inhibitor, Orlistat, on Serum Lipids and Lipoproteins in Patients with Primary Hyperlipidaemia. Eur. J. Clin. Pharmacol. 1994, 46, 405-410.
86. 3-Adrenergic Receptor mRNA in Human Tissues. Eur. J. Pharmacol. 1995, 289, 223-228.
87. Himms-Hageb, J. Brown Adipose Tissue Thermogenesis and Obesity. Prog. Lipid Res. 1989, 28, 67-115.
88. 3-Adrenergic Receptor and An Increased Capacity to Gain Weight in Patients with Morbid Obesity. N. Engl. J. Med. 1995, 333, 352-354.
89. 3-Adrenoceptor Polymorphism with Obesity and Diabetes: Current Status. Trends Pharmacol. Sci. 1997, 18, 449-454.
90. 3-Adrenergic Receptor. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 421-450.
91. 3 Adrenergic Agonist (BRL-37,344) Decreases Food Intake. Physiol. Behav. 1998, 63, 723-728.
92. 3-Adrenoceptor Agonists in the Treatment of Obesity and Diabetes. Int. J. Obes. 1996, 20, 191-199.
93. 3-Adrenergic Agonism: A New Concept in Human Pharmacotherapy; Futera: New York, 1995.
94. Galitzky, J.; Langin, D.; Montastruc, J.-L.; Lafontan, M.; Berlan, M. On the Presence of a Putative Fourth β-Adrenoceptor in Human Adipose Tissue. Trends Pharmacol. Sci. 1998, 19, 164-165.
95. 3-Adrenergic Agonists: Potential Therapeutics for Obesity. Exp. Opin. Invest. Drugs 1997, 6, 1811-1825.
96. Arch, J. R. S.; Ainsworth, A. T.; Cawthorne, M. A.; Piercy, V.; Sennitt, M. V.; Thody, V. E.; Wilson, C.; Wilson, S. Atypical β-Adrenoceptor on Brown Adipocytes as Target for Anti-Obesity Drugs. Nature 1984, 309, 163-165.
97. 3 Adrenergic Receptor. Selectivity is Enhanced at the Level of Receptor Binding. Med. Chem. Res. 1997, 7, 109-115.
98. Oriowo, M. A.; Chapman, H.; Kirkham, D. M.; Sennitt, M. V.; Ruffolo, R. R.; Cawthorne, M. A. The Selectivity In Vitro of the Stereoisomers of the β-3 Adrenoceptor Agonist BRL 37344. J. Pharmacol. Exp. Ther. 1996, 277, 22-27.
99. 3-Adrenergic Receptors: Differential Agonist Activation of Recombinant Receptors in Chinese Hamster Ovary Cells. Mol. Pharmacol. 1992, 42, 634-637.
100. Hollenga, C.; Haas, M.; Deinum, J. T.; Zaagsma, J. Discrepancies in Lipolytic Activities Induced by β-Adrenoceptor Agonists in Human and Rat Adipocytes. Horn. Metab. Res. 1990, 22, 17-21.
101. 3-Adrenoceptor Agonists of Differing Selectivities. J. Pharmacol. Exp. Ther. 1998, 285, 1084-1095.
102. 3-Adrenoceptor Agonists on Lipolysis in Human Omental Adipocytes. Int. J. Obes. 1996, 20, 428-434.
103. 3-Adrenoceptor Agonist, on Lipolysis of Human and Rat Adipocytes. Horm. Metab. Res. 1996, 28, 394-396.
104. 3-Adrenergic Agonist; Synthesis and Biological Activity of Indole Derivatives. Abstract of Papers; 214th National Meeting of the American Chemical Society, Las Vegas, NV; American Chemical Society: Washington, DC, 1997; MEDI 208.
105. Dow, R. L.; Wright, S. W. Preparation of Heterocyclic Compounds Containing Secondary Amines as Antidiabetic and Antiobesity Agents. WO 9429290, 1994; Chem. Abstr. 1995, 123, 198607.
106. 3-Adrenoceptor-Selective Agonist, is a Possible Therapeutic Agent for Non-Insulin-Dependent Diabetes Mellitus. Jpn. J. Pharmacol. 1997, 74, 109-112.
107. Manara, L.; Bianchetti, A. The Phenylethanolaminotetralins: New Selective Agonists for Atypical β-Adrenoceptors. Trends Pharmacol. Sci. 1990, 11, 229-230.
108. Cecchi, R.; Croci, T.; Boigegrain, R.; Boveri, S.; Baroni, M.; Boccardi, G.; Guimbard, J. P.; Guzzi, U. Synthesis and β-Adrenergic Activity of Atypical β-Adrenergic Phenylethanolaminotetralin Stereoisomers. Eur. J. Med. Chem. 1994, 29, 259-267.
109. Al-Qatari, M.; Taberner, P. V. Effects of SR-58611A, A Novel Atypical β-Adrenoceptor Agonist, on Brown Adipose Tissue Lipogenesis. Br. J. Pharmacol. 1992, 106, 65P.
110. Badone, D.; Guzzi, U. Synthesis of the Potent and Selective Atypical β-Adrenergic Agonist SR 59062A. Bioorg. Med. Chem. Lett. 1994, 4, 1921-1924.
111. 3 Agonists for the Treatment of Diabetes and Obesity. U.S. Patent 5,714,506, Feb 3, 1998.
112. 3 Adrenergic Receptor Agonists. Abstracts of Papers; 26th National Medicinal Chemistry Symposium, Richmond, VA, June 1998; Poster D-29.
113. 3 Agoinsts for the Treatment of Diabetes and Obesity. U.S. Patent 5,541,197, July 30, 1996.
114. 3 Agonists for the Treatment of Diabetes and Obesity. U.S. Patent 5,705,-515, Jan 6, 1998.
115. 3 Adrenergic Receptor Agonists for the Treatment of Type II Diabetes and Obesity. U.S. Patent 5,561,142, Oct 1, 1996.
116. 3 Binding Selectivity. Bioorg. Med. Chem. Lett. 1997, 7, 1583-1588 and references therein.
117. Sher, P. M.; Gavai, A.; Bisaacchi, G.; Mikkilineni, A.; Poss, K.; Cai, Z. Beta 3 Adrenoceptor Agonists Part III: Functional Selectivity Optimization Using Solid Phase Parallel Array Synthesis. Abstracts of Papers; 216th National Meeting of the American Chemical Society, Boston, MA; American Chemical Society: Washington, DC, 1998; MEDI 024.
118. Leo, A.; Mueller, M. Preparation of Bisphenethanolamine Derivatives as an Antiobesity and Antidiabetic Agent. Eur. Pat. Appl. EP 386603, 1990; Chem. Abstr. 1991, 114, 163719.
119. Leo, A.; Mueller, M. Oxazolidines. DE 3438411, 1985; Chem. Abstr. 1985, 103, 215273.
120. 3-Adrenoceptor Agonists. J. Heterocyl. Chem. 1995, 32, 1429-1439.
121. Leo, A.; Mueller, M. Phenoxypropanolamines. Eur. Pat. Appl. EP 14023, 1985; Chem. Abstr. 1986, 104, 68565.
122. Holloway, B. R.; Howe, R.; Rao, B. S.; Stribling, D. Thermogenic 2-Hydroxy-3-phenoxypropylamines and Processes for their Preparation. Eur. Pat. Appl. EP 210849, 1987; Chem. Abstr. 1987, 106, 138082.
123. 3-Adrenergic Agonists of Brown Adipose Tissue and Thermogenesis. 1. [4-[2-[(2-Hydroxy-3-phenoxvpropyl)amino]ethoxy]phenoxy]-acetates. J. Med. Chem. 1992, 35, 1751-1759.
124. 3-Adrenergic Agonists of Brown Adipose Tissue and Thermogenesis. 2. [4-[2-[(2-Hydroxy-3-phenoxypropyl)amino]ethoxy]phenoxy]-acetamides. J. Med. Chem. 1992, 35, 1759-1764.
125. 3 Adrenergic Receptor. Bioorg. Med. Chem. Lett. 1998, 8, 1101-1106.
126. 3 Adrenergic Receptor Agonist. Bioorg. Med. Chem. Lett. 1998, 8, 1107-1112.
127. 3-Adrenergic Receptor for the Treatment of Obesity. Abstracts of Papers; 213th National Meeting of the American Chemical Society, San Francisco, CA; American Chemical Society: Washington, DC, 1997; MEDI 168.
128. 3 Adrenergic Receptor with Improved Pharmacokinetic Properties. Bioorg. Med. Chem. Lett. 1998, 8, 2111-2116.
129. 3 Adrenergic Receptor Agonist. Bioorg. Med. Chem. Lett. 1996, 6, 2253-2258.
130. 3H]CGP-12177, Generally Classified as an Antagonist, is a Thermogenic Agonist in Brown Adipose Tissue. Biochem. J. 1989, 261, 401-405.
131. Beeley, L. J.; Berge, J. M.; Chapman, H.; Dean, D. K.; Kelly, J.; Lowden, K.; Kotecha, N. R.; Morgan, H. K. A.; Kami, H. K.; Thompson, M.; Vong, A. K. K.; Ward, R. W. A Simplified Template Approach Towards the Synthesis of a Potent Beta-3 Adrenoceptor Agonist at the Human Receptor. Bioorg. Med. Chem. Lett. 1997, 7, 219-224.
132. 3-Adrenergic Receptor Agonist for the Treatment of Obesity and NIDDM. Abstracts of Papers; 216th National Meeting of the American Chemical Society, Boston, MA; American Chemical Society: Washington, DC, 1998; MEDI 025.
133. 3-Selective Antagonists, Aryloxypropanolaminotetralins. Br. J. Pharmacol. 1996, 117, 435-442.
134. Gura, T. Uncoupling Proteins Provide a Clue to Obesity's Causes. Science 1998, 280, 1369-1370.
135. Klaus, S. L.; Casteilla, F., Bouillaud, F.; Ricquier, D. The Uncoupling Protein UCP: a Membraneous Mitochondrial Ion Carrier Exclusively Expressed in Brown Adipose Tissue. Int. J. Biochem. 1991, 23, 791-801.
136. Garlid, K. D.; Orosz, D. E.; Modriansky, S.; Vassanelli, S.; Jezek, P. J. On the Mechanism of Fatty Acid Induced Proton Transport by Mitochondrial Uncoupling Protein. J. Biol. Chem. 1996, 271, 2615-2620.
137. 3-Adrenergic Agonists. J. Clin. Invest. 1996, 97, 2898-2904.
138. Ghorbani, M.; Himms-Hagen, J. Appearance of Brown Adipocytes in White Adipose Tissue During CL 316,243-Induced Reversal of Obesity and Diabetes in Zucker fa/fa Rats. Int. J. Obes. 1997, 21, 465-475.
139. 3-Adrenergic Agonist Induces a Functionally Active Uncoupling Protein in Fat and Slow-Twitch Muscle Fibers. Am. J. Physiol. 1998, 274, E469-E475.
140. Fleury, C.; Neverova, M.; Collins, S.; Raimbault, S.; Champigny, O.; Levi-Meyrueis, C.; Bouillaud, F.; Seidin, M. F.; Surwit, R. S.; Ricquier, D.; Warden, C. H. Uncoupling Protein-2: A Novel Gene Linked to Obesity and Hyperinsulinemia. Nature Genet. 1997, 15, 269-272.
141. Gimenco, R. E.; Dembski, M.; Weng, X.; Deng, N.; Shyjan, A. W.; Gimenco, C. J.; Iris, F.; Ellis, S. J.; Woolf, E. A.; Tartaglia, L. A. Cloning and Characterization of an Uncoupling Protein Homolog. A Potential Molecular Mediator of Human Thermogenesis. Diabetes 1997, 46, 900-906.
142. Boss, O.; Samec, S.; Paoloni-Giacobino, A.; Rossier, C.; Dulloo, A.; Seydoux, J.; Muzzin, P.; Giacobino, J.-P. Uncoupling Protein-3: A New Member of the Mitochondrial Carrier Family with Tissue Specific Expression. FEBS Lett. 1997, 408, 39-42.
143. Vidal-Puig, A.; Solanes, G.; Grujic, D.; Flier, J. S.; Lowell, B. B. UCP3: An Uncoupling Protein Homologue Expressed Preferentially and Abundantly in Skeletal Muscle and Brown Adipose Tissue. Biochem. Biophys. Res. Commun. 1997, 235, 79-82.
144. Auwerx, J.; Martin, G.; Guerre-Millo, M.; Staels, B. Transcription, Adipocyte Differentiation, and Obesity. J. Mol. Med. 1996, 74, 347-352.
145. Matsuda, J.; Hosoda, K.; Itoh, H.; Son, C.; Doi, K.; Tanaka, T.; Fukunaga, Y.; Inoue, G.; Nishimura, H.; Yoshimasa, Y.; Yamori, Y.; Nakao, K. Cloning of Rat Uncoupling Protein-3 and Uncoupling Protein-2 cDNAs: Their Gene Expression in Rats Fed High-Fat Diet. FEBS Lett. 1997, 478, 200-204.
146. Gong, D.-W.; He, Y.; Karas, M.; Reitman, M. Uncoupling Protein-3 is a Mediator of Thermogenesis Regulated by Thyroid Hormone, β3-Adrenergic Agonists, and Leptin. J. Biol. Chem. 1997, 272, 24129-24132.
147. Tontonoz, P.; Hu, E.; Spiegelman, B. M. Regulation of Adipocyte Gene Expression and Differentiation by Peroxisome Proliferator Activated Receptor γ. Curr. Opin. Genet. Dev. 1995, 5, 571-576.
148. Schoonjans, K.; Staels, B.; Auwerx, J. Role of the Peroxisome Proliferator Activated Receptor (PPAR) in Mediating Effects of Fibrates and Fatty Acids on Gene Expression. J. Lipid Res. 1996, 37, 907-925.
149. Zhu, Y.; Qi, C.; Korenberg, J. R.; Chen, X.-N.; Noya, D.; Rao, M. S.; Reddy, J. K. Structural Organization of Mouse Peroxisome Proliferator Activated Receptor γ (mPPARγ) Gene: Alternative Promoter Use and Different Splicing Yield Two mPPARγ Isoforms. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7921-7925.
150. Spiegelman, B. M.; Flier, J. S. Adipogenesis and Obesity: Rounding Out the Big Picture. Cell 1996, 87, 377-389.
151. Spiegelman, B. M. Peroxisome Proliferator-Activated Receptor Gamma: a Key Regulator of Adipogenesis and Systemic Insulin Sensitivity. Eur. J. Med. Res. 1997, 2, 257-264.
152. Green, S.; Wahli, W. Peroxisome Proliferator-Activated Receptors: Finding the Orphan a Home. Mol. Cell. Endocrinol. 1994, 100, 149-153.
153. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkinson, W. O.; Wilson, T. M.; Kliewer, S. A. An Anti-Diabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor Gamma. J. Biol. Chem. 1995. 270, 12953-12956.
154. 12,14-prostaglandin J2 is a Ligand for the Adipocyte Determination Factor PPARγ. Cell 1995, 83, 803-812.
155. Brun, R. P.; Tontonoz, P.; Forman, B. M.; Ellis, R.; Chen, J.; Evans, R. M.; Spiegelman, B. M. Differential Activation of Adipogenesis by Multiple PPAR Isoforms. Genes Dev. 1996,10, 974-984.
156. Simmott, M. L. Catalytic Mechanism of Enzymic Glycosyl Transfer. Chem. Rev. 1990, 90, 1171-1202.
157. Scafer, G. Some New Aspects on the Interaction of Hypoglycemia-Producing Biguanides with Biological Markers. Biochem. Pharmacol. 1976, 25, 2015-2024.
158. Hollobaugh, S. L.; Rao, M. B.; Kruger, F. A. Site and Mechanism of Action of Phenformin. I. Evidence for Significant "Nonperipheral" Effects of Phenformin on Glucose Metabolism in Normal Subjects. Diabetes 1970, 19, 45-49.
159. D'Alessio, D. A.; Thirlby, R.; Laschansky, E. C.; Zebroski, H.; Ensinck, J. W. Response of GLP-1 to Nutrients in Humans. Digestion 1993, 54, 377-379.
160. Hermann, C.; Goke, R.; Richter, H. C.; Fehman, H. C.; Arnbold, R.; Goke, B. Glucagon-Like Peptide-1 and Glucose-Dependent Insulin-Releasing Polypeptide Plasma Levels in Response to Nutrients. Digestion 1995, 56, 117-126.
161. D'Alessio, D. A.; Vogel, R.; Prigeon, R. L.; Laschansky, D.; Koerker, D.; Eng, J.; Ensinck, J. W. Elimination of the Action of Glucagon-Like Peptide-1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion by Healthy Humans. J. Clin. Invest. 1996, 97, 133-138.
162. Goke, R.; Larsen, P. J.; Mikkelsen, S. P.; Skeikh, S. P. Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that Exendin is a Ligand of Brain GLP-1 sites. Eur. J. Neurosci. 1995, 2294-2300.
163. Gunn, I.; O'Shea, D.; Bloom, S. R. Control of Appetite-The Role of Glucagon-Like Peptide-1 (7-36) Amide. J. Endocrinol. 1997, 155, 197-200.
164. McMahon, L. R.; Wellman, P. J. PVN Infusion of GLP-1-(7-36) Amide Suppresses Feeding but Does Not Induce Aversion or Alter Locomotion in Rats. Am. J. Physiol. 1998, 274, R23-R29.
165. Crawley, J. N.; Corwin, R. L. Biological Actions of Cholecystokinin. Peptides 1994, 15, 731-755.
166. Dourish, C. T.; Hill, D. R. Classification and Function of CCK Receptors. Trends Pharmacol. Sci. 1987, 8, 207-208.
167. Crawley, J. N.; Fiske, S. M.; Durieux, C.; Derrien, M.; Roques, B. P. Centrally Administered Cholecystokinin Suppresses Feeding Through a Peripheral-Type Receptor Mechanism. J. Pharmacol. Exp. Ther. 1991, 257, 1076-1080.
168. Blundell, J. Pharmacological Approaches to Appetite Suppression. Trends Pharmacol. Sci. 1991, 12, 147-157.
169. Silver, A. J.; Morley, J. E. Role of CCK in Regulation of Food Intake. Prog. Neurobiol. 1991, 36, 23-34.
170. Gibbs, J.; Young, R. C.; Smith, G. P. Cholesystokinin Decreased Food Intake in Rats. J. Comput. Physiol. Psychol. 1973, 84, 488-495.
171. Kissilef, H. R.; Pi-Sunyer, F. X.; Thornton, J.; Smith, G. P. C-Terminal Octapeptide of Cholecystokinin Decreases Food Intake in Man. Am. J. Clin. Nutr. 1981, 34, 154-160.
172. Pi-Sunyer, X.; Kissilef, H. R.; Thornton, J.; Smith, G. P. C-Terminal Octapeptide of Cholecystokinin Decreases Food Intake in Obese Men. Physiol. Behav. 1982, 29, 627-630.
173. West, D. B.; Fey, D.; Woods, S. C. Cholecystokinin Persistently Suppresses Meal Size but not Food Intake in Free-Feeding Rats. Am. J. Physiol. 1984, 246, R776-R787.
174. Hermkens, P. H. H.; Ottenheijm, H. C. J.; van der Werf-Pieters, J. M. L.; Broekkamo, C. L. E.; deBoer, T.; van Nispen, J. W. CCK-A Agonists: Endeavours Involving Structure-Activity Relationship Studies. Red. Trav. Chim. Pays-Bas 1993, 112, 95-106.
175. Holladay, M. W.; Bennett, M. J.; Tufano, M. D.; Lin, C. W.; Asin, K. E.; Witte, D. G.; Miller, T. R.; Bianchi, B. R.; Nikkel, A. L. Synthesis and Biological Activity of CCK-Heptapeptide Analogues. Effects of Conformational Constraints and Standard Modifications on Receptor Subtype Selectivity, Functional Activity in vitro and Appetite Suppression in vivo. J. Med. Chem. 1992, 35, 2919-2928.
176. Lin, C. W.; Holladay, M. W.; Witte, D. G.; Miller, T. R.; Wolfram, C. A. W.; Bianchi, B. R.; Bennett, M. J.; Nadzan, A. M. A71378: CCK Agonist with High Potency and Selectivity for CCK-A Receptors. Am. J. Physiol 1990, 258, G648-G651.
177. Voits, M.; Voigt, J.-P.; Boomgaarden, M.; Henklein, P.; Fink, H. Comparison of the Satiating Effect of the CCK-A Receptor Agonist A71378 with CCK-8. Peptides 1996, 17, 355-357.
178. Asin, K. E.; Gore, P. A., Jr.; Bednarz, L.; Holladay, M.; Nadzan, A. M. Effects of Selective CCK Receptor Agonists on Food Intake After Central or Peripheral Administration in Rats. Brain Res. 1992, 571, 169-174.
179. Asin, K. E.; Bedmarz, L.; Nikkel, A. L.; Gore, P. A., Jr.; Nadzan, A. M. A-71623, A Selective CCK-A Receptor Agonist, Suppresses Food Intake in the Mouse, Dog and Monkey. Pharmacol. Biochem. Behav. 1992, 42, 699-704.
180. Pierson, M. E.; Comstock, J. M.; Simmons, R. D.; Kaiser, F.; Julien, R.; Zongrone, J.; Rosamond, J. D. Synthesis and Biological Evaluation of Potent, Selective, Hexapeptide CCK-A Agonist Anorectic Agents. J. Med. Chem. 1997, 40, 4302-4307.
181. Simmons, R. D.; Blosser, J. C.; Rosamond, J. D. ARL 14294: A Novel CCK-8 Agonist with Potent Intranasal Anorectic Activity in the Rat. Pharmacol. Biochem. Behav. 1994, 47, 701-708.
182. Simmons, R. D.; Kaiser, F. C.; Pierson, M. E.; Rosamond, J. R. ARL 15849: A Selective CCK-A Agonist with Anorectic Activity in the Rat and Dog. Pharmacol. Biochem. Behav. 1998, 59, 439-444.
183. Aquino, C. J.; Armour, D. R.; Berman, J. M.; Birkemo, L. S.; Carr, R. A. E.; Croom, D. K.; Dezube, M.; Dougherty, R. W., Jr.; Ervin, G. N.; Grizzle, M. K.; Head, J. E.; Hirst, G. C.; James, M. K.; Johnson, M. F.; Miller, L. J.; Queen, K. L.; Rimele, T. J.; Smith, D. N.; Sugg, E. E. Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger". J. Med. Chem. 1996, 39, 562-569.
184. Hirst, G. C.; Queen, K. L.; Sugg, E. E.; Willson, T. M. Conversion of Acyclic Nonpeptide CCK Antagonists into CCK Agonists. Bioorg. Med. Chem. Lett. 1997, 7, 511-514.
185. Henke, B. R.; Willson, R. M.; Sugg, E. E.; Croom, D. K.; Dougherty, R. W., Jr.; Queen, K. L.; Birkemo, L. S.; Ervin, G. N.; Grizzle, M. K.; Johnson, M. F.; James, M. K. 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A Agonists That Demonstrate Oral Activity as Satiety Agents. J. Med. Chem. 1996, 39, 2655-2658.
186. Henke, B. R.; Aquino, C. J.; Birkemo, L. S.; Croom, D. K.; Dougherty, R. W., Jr.; Ervin, G. N.; Grizzle, M. K.; Hirst, G. C.; James, M. K.; Johnson, M. F.; Queen, K. L.; Sherrill, R. G.; Sugg, E. E.; Suh, E. M.; Szewczyk, J. W.; Unwalla, R. J.; Yingling, J.; Willson, T. M. Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists. J. Med. Chem. 1997, 40, 2706-2725.
187. Rose, C.; Vargas, F.; Facchinetti, P.; Bourgeat, P.; Bambal, R. B.; Bishop, P. B.; Chan, S. M. T.; Moore, A. N. J.; Ganellin, C. R.; Schwartz, J.-C. Characterization and Inhibition of a Cholecystokinin-Inactivating Serine Peptidase. Nature 1996, 380, 403-409.
188. Ganellin, C. R.; Bishop, P. B.; Bambal, R. B.; Chan, S. M. T.; Moore, A. N. J.; Bourgeat, P.; Rose, C.; Vargas, F.; Schwartz, J.-C. Design of Protease Inhibitors from Structures of Substrate Products. The Example of Butabindide, an Inhibitor of the Cholecystokinin (CCK-8)-Inactivating Peptidase. Abstracts of Papers; 213th National Meeting of the American Chemical Society, San Francisco, CA; American Chemical Society: Washington, DC, 1997; MEDI 305.
189. Stephens, T. W.; Caro, J. F. To be Lean or not to be Lean. Is Leptin the Answer? Exp. Clin. Endocrinol. Diabetes 1998, 106, 1-15.
190. Tritos, N. A.; Mantzoros, C. S. Leptin: Its Role in Obesity and Beyond. Diabetologia 1997, 40, 1371-1379.
191. Considine, R. V.; Caro, J. F. Leptin and the Regulation of Body Weight. Int. J. Biochem. Cell Biol. 1997, 29, 1255-1272.
192. Dallongeville, J.; Fruchart, J.-C.; Auwerx, J. Leptin, A Pleiotropic Hormone: Physiology, Pharmacology, and Strategies for Discovery of Leptin Modulators. J. Med. Chem. 1998, 41, 5337-5352.
193. Kennedy, G. C. The Role of Depot Fat in the Hypothalamic Control of Food Intake in the Rat. Proc. R. Soc. 1953, 140, 578-592.
194. Murakami, T.; Shima, K. Cloning of Rat Obese cDNA and its Expression in Obese Rats. Biochem. Biophys. Res. Commun. 1995, 209, 944-952.
195. Ogawa, Y.; Masuzaki, H.; Isse, N.; Okazaki, T.; Mori, K.; Shigemoto, M.; Satoh, N.; Tamura, N.; Hosoda, K.; Yoshimasa, Y.; Jingami, H.; Kawada, T.; Nakao, K. Molecular Cloning of Rat Obese cDNA and Augmented Gene Expression in Genetically Obese Zucker Fatty (fa/fa) rats. J. Clin. Invest. 1995, 96, 1647-1652.
196. Madej, T.; Boguski, M. S.; Bryant, S. H. Threading Analysis Suggests that the Obese Gene Product may be a Helical Cytokine. FEBS Lett. 1995, 373, 13-18.
197. Zhang, F.; Basinski, M. B.; Beals, J. M.; Briggs, S. L.; Churgay, L. M.; Clawson, D. K.; Dimarchi, R. D.; Furman, T. C.; Hale, J. E.; Hsiung, H. M.; Schoner, B. E.; Smith, D. P.; Zhang, X. Y.; Wery, J. P.; Schevitz, R. W. Crystal Structure of the Obese Protein Leptin-E100. Nature 1997, 387, 206-209.
198. Tartaglia, L. A.; Dembski, M.; Weng, X.; Deng, N.; Culpepper, J.; Devos, R.; Richards, G. J.; Campfield, L. A., Clark, F. T.; Deed, J.; Muir, C.; Sanker, S.; Moriarty, A.; Moore, K. J.; Smutko, J. S.; Mays, G. G.; Woolf, E. A.; Monroe, C. A.; Tepper, R. I. Identification and Expression Cloning of a Leptin Receptor, OB-R. Cell 1995, 83, 1263-1271.
199. Takaya, K.; Ogawa, Y.; Isse, N.; Okazaki, T.; Satoh, N.; Masuzaki, H.; Mori, K.; Tamura, N.; Hosoda, K.; Nakao, K. Molecular Cloning of Rat Leptin Receptor Isoform cDNAs-Identification of a Missense Mutation in Zucker Fatty Rats. Biochem. Biophys. Res. Commun. 1996, 225, 75-83.
200. Mercer, J. G.; Hogard, N.; Williams, L. M.; Lawrence, C. B.; Hannah, L. T.; Trayhyrn, P. Localization of Leptin Receptor mRNA and the Long Form Splice Variant (Ob-Rb) in Mouse Hypothalamus and Adjacent Brain Regions by in situ Hydridization. FEBS Lett. 1996, 387, 113-116.
201. Bauman, H.; Morella, K. K.; White, D. W.; Dembski, M.; Bailon, P. S.; Kim, H.; Lai, C.-F.; Tartaglia, L. A. The Full Length Leptin Receptor has Signaling Capabilities of Interleukin-6-type Cytokine Receptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8374-8378.
202. Halaas, J. L.; Gajiwala, K. S.; Maffei, M.; Cohen, S. L.; Chait, B. T.; Rabinowitz, D.; Lallone, R. L.; Burley, S. K.; Friedman, J. M. Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene. Science 1995, 269, 543-546.
203. Pelleymounter, M. A.; Cullen, M. J.; Baker, M. B.; Hecht, R.; Winters, D.; Boone, T.; Collins, F. Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice. Science 1995, 269, 540-543.
204. Considine, R. V.; Sinha, M. K.; Heiman, M. L.; Kriauciunas, A.; Stephens, T. W.; Nyce, M. R.; Ohannesian, J. P.; Marco, C. C.; McKee, L. J.; Bauer, T. L.; Caro, J. F. Serum Immunoreactive Leptin Concentrations in Normal Weight and Obese Humans. N. Engl. J. Med. 1996, 334, 292-295.
205. Sinha, M. K.; Opentanova, I.; Ohannesian, J. P.; Kolaczynski, J. W.; Heiman, M. L.; Hale, J.; Becker, G. W.; Bowsher, R. R.; Stephens, T. W.; Caro, J. F. Evidence of Free and Bound Leptin in Human Circulation: Studies in Lean and Obese Subjects and During Short-Term Fasting. J. Clin. Invest. 1996, 98, 1277-1282.
206. Caro, J. F.; Kolaczynski, J. W.; Nyce, M. R.; Ohannesian, J. P.; Opentanova, I.; Goldman, W. H.; Lynn, R. B.; Zhang, P.-L.; Sinha, M. K.; Considine, R. V. Decreased Cerebrospinal Fluid/ Serum Leptin Ratio in Obesity; a Possible Mechanism for Leptin Resistance. Lancet 1996, 348, 159-161.
207. Kristensen, P.; Judge, M. E.; Thim, L.; Ribel, U.; Christjansen, K. N.; Wulff, B. S.; Clausen, J. T.; Jensen, P. B.; Madsen, O. D.; Vrang, N.; Larsen, P. J.; Hastrup, S. Hypothalamic CART is a New Anorectic Peptide Regulated by Leptin. Nature 1998, 393, 72-76.
208. Rink, T. J.; Beaumont, K.; Joy, K.; Young, A. Structure and Biology of Amylin. Trends Pharmacol. Sci. 1993, 14, 113-118.
209. Morley, J. E.; Horowitz, J. F.; Morley, P. M. K.; Walter, M. J. Modulation of Food Intake by Peripherally Administered Amylin. Am. J. Physiol. 1994, 267, R178-R179.
210. Gehlert, D. R. Multiple Receptors for the Pancreatic Polypeptide (PP-Fold) Family: Physiological Implications. Proc. Soc. Exp. Biol. Med. 1998, 218, 7-22.
211. Zimanyi, I. A.; Fathi, Z.; Poindexter, G. S. Central Control of Feeding Behavior by Neuropeptide Y. Curr. Pharm. Des. 1998, 4, 349-366.
212. Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, A. O.; Whitebread, S.; Hofbauer, K. G.; Taber, R. I.; Branchek, T. A.; Weinshank, R. L. A Receptor Subtype Involved in Neuropeptide-Y-Induced Food Intake. Nature 1996, 382, 168-171.
213. Schaffhauser, A. O.; Stricker-Krongrad, A.; Brunner, L.; Cumin, F.; Gerald, C.; Whitebread, S.; Criscione, L.; Hofbauer, K. G. Inhibition of Food Intake by Neuropeptide Y Y5 Receptor Antisense Oligodeoxynucleotides. Diabetes 1997, 46, 1792-1798.
214. Wyss, P.; Levens, N.; Strickei-Krongrad, A. Stimulation of Feeding in Lean but not in Obese Zucker Rats by a Selective Neuropeptide Y Y5 Receptor Agonist. NeuroReport 1998, 9, 2675-2677.
215. Borowsky, B.; Walker, M. W.; Bard, J.; Weinshank, R. L.; Laz, T. M.; Vaysse, P.; Branchek, T. A.; Gerald, C. Molecular Biology and Pharmacology of Multiple NPY Y5 Receptor Homologues. Regul. Pept. 1998, 75-76, 43-53.
216. Kask, A.; Rago, L.; Harro, J. Evidence for Involvment of Neuropeptide Y Receptors in the Regulation of Food Intake: Studies with Y1-Selective Antagonist BIBP 3226. Br. J. Pharmacol. 1998, 124, 1507-1515.
217. Erickson, J. C.; Hollopater, G.; Palmiter, R. D. Attenuation of the Obesity Syndrome of ob/ob Mice by the Loss of Neuropeptide Y. Nature 1996, 274, 1704-1707.
218. Itoh, E.; Fujimiya, M.; Inui, A. Thioperamide, a Histamine H3 Receptor Antagonist, Suppresses NPY-but not Dynorphin-A-Induced Feeding in Rats. Regul. Pept. 1998, 75-76, 373-376.
219. Doods, H. N.; Wieland, H. A.; Engel, W. BIBP 3226, The First Selective Neuropeptide Y1 Receptor Antagonist: A Review of its Pharmacological Properties. Regul. Pept. 1996, 65, 71-77.
220. Peterson, J. M.; Blum, C. A.; Hutchinson, A. Certain Substituted Benzylamine Derivatives: A New Class of Neuropeptide Y1 Specific Ligands. WO 96/143307, 1996.
221. Zarrinmayeh, H.; Nunes, A. M.; Ornstein, P. L.; Zimmerman, D. M.; Arnold, M. B.; Shober, D. A.; Gackenheimer, S. L.; Bruns, R. F.; Hipskind, P. A.; Britton, T. C.; Cantrell, B. E.; Gehlert, D. R. Synthesis and Evaluation of a Series of Novel 2-[(4-Chlorophenoxy)methyl]benzamides as Selective Neuropeptide Y Y1 Receptor Antagonists. J. Med. Chem. 1998, 41, 2709-2719.
222. Rueger, H.; Yamaguchi, Y.; Tintelnot-Blomley, M.; Sailing, W. Quinazolin-2,4-diazirines as NPY Receptor Antagonists. WO 97/ 20822, 1997.
223. Rueger, H.; Schmidlin, T.; Rigollier, P.; Yamagichi, Y. New Quinazoline Derivatives are NPY Y5 Receptor Antagonists. WO 97/20283-A2, 1997.
224. Fukami, T.; Fukuroda, T.; Kanatani, A.; Ihara, M. New Aminopyrazoles are Neuropeptide Y Antagonists-Useful for the Treatment of e.g. Bulimia, Obesity and Diabetes. WO 98/27063-A1, 1998.
225. Fukami, T.; Fukuroda, T.; Kanatani, A.; Ihara, M. New Carbonylamino-prazole Derivatives are Neuropeptide Y Antagonists - Useful for Treating e.g. Bulimia, Obesity and Diabetes. WO 98/25907, 1998.]
226. Fukami, T.; Okamoto, O.; Fukuroda, T.; Kanatani, A.; Ihara, M. Use of Aminopyridine Derivatives as Neuropeptide Y Receptor Antagonists - for the Treatment of Obesity, Bulimia and Diabetes, and for Prevention and Treatment of Hypertension, Kidney Diseases, Cardiac Diseases, Circulation Disorders, Dementia, Depression, Anxiety and Hormone Disorders. WO 98/ 40356-A1, 1998.
227. Connell, R. D.; Lease, T. G.; Ladouceur, G. H.; Osterhout, M. H. Use of Amide Derivatives as Selective NPY Y5 Receptor Antagonists - for the Treatment of e.g. Obesity, Bulimia, Type II Diabetes, Hypertension, Pulmonary Disease, Memory Disorders, Epilepsy. Dyslipidemia and Depression. WO 98/355957-A1, 1998.
228. Tatro, J. B. Receptor Biology of the Melanocortins, A Family of Neuroimmunomodulatory Peptides. Neuroimmunology 1996, 3, 259-284.
229. Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D. Role of Melanocortinergic Neurons in Feeding and the Agouti Obesity Syndrome. Nature 1997, 385, 165-168.
230. Huszar, D.; Lynch, C. A.; Fairchild-Huntress, V.; Dunmore, J. H.; Fang, Q.; Berkemeier, L. R.; Gu, W.; Kesterson, R. A.; Boston, B. A.; Cone, R. D.; Smith, F. J.; Campfield, L. A.; Burn, P.; Lee, F. Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice. Cell 1997, 76, 131-141.
231. Seeley, R. J.; Yagaloff, K. A.; Fisher, S. L.; Burn, P.; Thiele, T. E.; van Dijk, G.; Baskin, B.; Schwartz, M. W. Melanocortin Receptors in Leptin Effects. Nature 1997, 390, 349-351.
232. Kask, A.; Rago, L.; Korrovits, P.; Wikberg, J. E. S.; Schioth, H. B. Evidence that Orexigenic Effects of Melanocortin 4 Receptor Antagonist HSO14 are Mediated by Neuropeptide Y. Biochem. Biophys. Res. Commun. 1998, 248, 245-249.
233. Kask, K.; Berthold, M.; Bartfai, T. Galanin Receptors: Involvement in Feeding, Pain, Depression and Alzheimer's Disease. Life Sci. 1997, 60, 1523-1533.
234. Leibowitz, S. F.; Akabayashi, A.; Wang, J. Obesity on a High-Fat Diet: Role of Hypothalamic Galanin in Neurons of the Anterior Paraventricular Nucleus Projecting to the Median Eminence. J. Neurosci. 1998, 18, 2709-2719.
235. McCoy, J. G.; Avery, D. D. Bombesin: Potential Integrative Peptide for Feeding and Satiety. Peptides 1990, 11, 595-607.
236. Ohki-Hamazaki, H.; Watase, K.; Yamamoto, K.; Ogura, H.; Yamano, M.; Yamada, K.; Maeno, H.; Imaki, J.; Kikuyama, S.; Wada, E.; Wada, K. Mice Lacking Bombesin Receptor Subtype-3 Develop Metabolic Defects and Obesity. Nature 1997, 390, 165-169.
237. Erlanson-Albertsson, C.; York, D. Enterostatin - A Peptide Regulating Fat Intake. Obes. Res. 1997, 5, 360-372.
238. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R. M.; Tanaka, H.; Williams, S. C.; Richardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R. S.; Buckingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W.-S.; Terrett, J. A.; Elshourbagy, N. A.; Bergsma, D. J.; Yanagisawa, M. Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior. Cell 1998, 92, 573-585.
239. de Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.-B.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L. F.; Gautvik, V. T.; Bartlett, F. S., II; Frankel, W. N.; van den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Suteliffe, J. G. The Hypocretins: Hypothalamus-Specific Peptides with Neuroexcitatory Activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 322-327.